Deaths / year
—
GBD (indicative unless refreshed)
DALYs / year
—
GBD
Pathogen
Fungus
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic progressive subcutaneous destruction, disability, amputation
Classification
Chronic disease
Onset
chronic by nature
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO mycetoma
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Footwear & wound protection | Prevention | Approved | Reduce traumatic inoculation in endemic areas | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Itraconazole | Antifungal | Approved | Eumycetoma (fungal) | WHO EML / standard of care |
| Ketoconazole | Antifungal | Approved | Alternative azole | WHO EML / standard of care |
| Amoxicillin–clavulanate + gentamicin | Antibiotic combination | Approved | Actinomycetoma (bacterial) | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Surgical debridement & amputation (advanced) | Surgery | Approved | Chronic destructive disease | WHO mycetoma |
Associated drug targets (Open Targets): CYP51A1, IL17A, IL10, IL1B, IL37, IFNG
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005757 · Updated 2026-07-10. Associations, not a diagnostic test.